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Abstract
Background: When investigating subgroup effects in meta-analysis, it is unclear whether accounting in meta-
regression for between-trial variation in treatment effects, but not between-trial variation in treatment interaction
effects when such effects are present, leads to biased estimates, coverage problems, or wrong standard errors, and
whether the use of aggregate data (AD) or individual-patient-data (IPD) influences this assessment.
Methods: Seven different models were compared in a simulation study. Models differed regarding the use of AD
or IPD, whether they accounted for between-trial variation in interaction effects, and whether they minimized the
risk of ecological fallacy.
Results: Models that used IPD and that allowed for between-trial variation of the interaction effect had less bias,
better coverage, and more accurate standard errors than models that used AD or ignored this variation. The main
factor influencing the performance of models was whether they used IPD or AD. The model that used AD had a
considerably worse performance than all models that used IPD, especially when a low number of trials was
included in the analysis.
Conclusions: The results indicate that IPD models that allow for the between-trial variation in interaction effects
should be given preference whenever investigating subgroup effects within a meta-analysis.
Keywords: Individual patient data, Meta-analysis, Random-effects, Evidence synthesis, Interaction effects, Subgroup
analysis
Background
Meta-analysis is an essential tool for evidence-based
clinical practice [1]. It allows the combination of
treatment effect estimates across two or more trials,
which has two main advantages. First, it provides a
summary treatment effect estimate for patient, clini-
cians, or policy-makers seeking information about the
effectiveness of a treatment. Because these stake-
holders are commonly faced with a large number of
scientific literature publications on which they need
to base their decisions, a summary treatment effect
estimate(s) is(are) (or summary distribution of treat-
ment effects, in the presence of heterogeneity when
random effect models are used) likely to facilitate the
decision-making process. Second, it provides a more
precise treatment effect estimate, that is, a treatment
effect with narrower confidence intervals, minimizing
sampling error. Randomized controlled trials (RCTs)
are considered the gold-standard study design to in-
vestigate the effectiveness of treatment interventions
[2]. Meta-analyses of randomized controlled trials
offer, therefore, the optimal basis for evidence-based
clinical practice.
The data used to conduct a meta-analysis can be
of two forms: an average treatment effect from each
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study, such as a difference in means for continuous
outcomes or a risk ratio for binary outcomes, or it
can be at the patient level, where the outcome of
interest is available individually for each of the pa-
tients included in the trial [3]. The vast majority of
meta-analyses are based on average treatment effects,
which are commonly referred to as aggregate data (AD)
meta-analyses, while a small proportion use individual pa-
tient data (IPD) or a combination of AD and IPD [3, 4].
The reason why most meta-analyses use AD is because
they are readily available in published, publicly available
reports of RCTs. Getting access to IPD is usually difficult
or even impossible, as in most cases IPD are not publicly
available, clinical trialists often choose not to share them,
or datasets have been lost or misplaced [5]. However, the
use of IPD in meta-analysis offers significant statistical ad-
vantages, such as more precise results with narrower con-
fidence intervals in some scenarios or the proper
investigation of subgroup treatment effects [6].
Investigation of subgroup effects is an important
part of clinical research [7]. While a treatment may
be of low clinical relevance in the broader population
of patients with a particular disease, we may identify
subgroups of patients who may significantly benefit
from this treatment. An intuitive example would be
weight reduction in patients with knee osteoarthritis
(OA) [8]. While weight reduction may have a signifi-
cant effect on the knee pain of OA patients who are
overweight, it would not work or even be detrimental
for those patients with normal or below normal body
weight. The investigation of the source of variation of
treatment effects between patients is therefore of cru-
cial relevance for the use of trial findings in the clin-
ical setting. Otherwise, useful treatments may be
discarded solely based on its irrelevant effect at the
overall patient population or we may fail to identify
subgroups of patients who are more likely to respond
to a treatment that only has a negligible effect in the
overall patient population of interest.
Subgroup analyses in single trials are often under-
powered since RCTs are generally only powered to
identify a treatment effect at the overall patient popu-
lation. Because of this, meta-analyses that combine data
from several trials become a powerful tool in conducting
subgroup analyses that have enough statistical power to
identify minimal clinically relevant treatment effects in
specific subgroups of patients. The investigation of sub-
group effects within a meta-analysis can be conducted
using meta-regression. Regression analyses can be used to
explain the variation of treatment effects across different
trials [9]. Both patient and trial level characteristics can be
used in these regression analyses. While the investigation
of the influence of trial level characteristics, such as meth-
odological quality, in the variation of treatment effects can
be done using either AD or IPD, the investigation of patient
level characteristics, such as age or gender, using only AD
may be biased due to ecological fallacy (also known as
aggregation bias) since average patient characteristics are
regressed against average trial outcomes [10]. Thus, regres-
sion analyses using IPD is considered the gold standard
when investigating subgroup effects of patient-level charac-
teristics in a meta-analysis since individual patient’s charac-
teristics can be regressed against the individual’s outcome.
In meta-analysis, it is usually considered important
to take into account the between-trial variation in
the effect of interest that is being pooled across tri-
als. For instance, when meta-analyzing treatment ef-
fects across trials, we may notice a considerable
between-trial variation. This indicates that there is
variability around the overall treatment effect esti-
mate, which may be caused by more than just
chance (i.e. sampling error). When this is the case, it
is important to use methods that incorporate this
additional variability in the estimation of confidence
intervals around the pooled effect estimate. This is
done in meta-analysis by using a random-effects ap-
proach, which accounts for the between-trial vari-
ation in the treatment effect [11, 12] and allows for
the distribution of effects to be quantified [13]. Like-
wise, it may be important to take into account the
between-trial variation in the interaction effect be-
tween patient-level characteristics and treatment ef-
fect, when using regression analyses to conduct
subgroup analyses in a meta-analyses. However, re-
gression models implemented in statistical software
usually account only for between-trial variation in
the treatment effect when pooling interaction effects
across trials. It is unclear whether accounting for
between-trial variance only in treatment effects, but
not in interaction effects, leads to biased estimates,
coverage problems, or under or overestimation of
standard errors, when estimating overall mean ef-
fects, and whether this could be influenced by the
use of AD or IPD data for the analysis.
Thus, the main purpose of this simulation study is to
understand whether the current approach for combining
interaction effects, which accounts only for between-trial
variation in treatment effects, but ignores the variation
of interaction effects across trials, leads to a suboptimal
estimation of a pooled interaction effect across trials. In
Methods section, the methods used in the current simu-
lation study, including a description of the statistical
models and performance measures used in this investi-
gation will be described. In Results section, the results of
the simulation analyses will be presented. In Discussion
section, the results will be discussed in the context of
previous investigations; limitations and strengths will be
described, and conclusions will be presented.
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Methods
We now describe i) the methods used to generate the
simulated datasets used for the performance analysis; ii)
the analysis models that will be compared; and iii) the
performance measures that will be used to compare
these models. The reporting of the methods and results
of this simulation study follow the guidelines proposed
by Morris et al. and Burton et al. [14, 15].
Data-generating mechanisms
Linear predictor used for data generation
A framework was developed to investigate how dif-
ferent models for the assessment of treatment inter-
action effects in meta-analyses with continuous
outcomes perform. Thus, we simulated datasets in
order to assess the performance of different models
to quantify the interaction between treatment effect
and patients’ age within an IPD meta-analysis
framework. We assume a linear association between
age and knee OA pain, and a linear association be-
tween age and the treatment effect. The simulated
data mimicked trials of high dose Naproxen com-
pared with placebo for the treatment of knee OA
pain quantified with a single assessment at the end
of treatment using a 10-cm visual analogue scale
(VAS), where 0 means no pain and 10 means the
worst imaginable pain [16].
The following linear predictor was used to simulate
this dataset (Table 1):
yij ¼ 6:0þ treatijbeta:treati
 þ ageij0:1
 
þ treatijageijbeta:interi
 
þ uij
þvijtreatij þ εijuij  N 0; σ2
 
;
vij  N 0; τ2
 
; cov uij; vij
  ¼ ρστ
εij  N 0; res: varið Þ beta:treati  N
−1:0;V 1ð Þ beta:interi  N δ;V 2ð Þ ageij  N
mean:agei; variance:agei
 
mean:agei  N
67; 20:25ð Þ variance:agei  N 49; 1ð Þ
ð4:1Þ
where yij is the predicted knee OA pain measured on a 0
Table 1 Varying and fixed parameters of simulated datasets that were used to compare the performance measures of different
models
Parameters Value in simulation Statistical notation in the linear predictor used
for simulation of datasetb
Varying-parameters
Number of trials 6, 10, 16, 20, 26, 30, 40, 50 –
Magnitude of the interaction effecta 0, −0.01 beta.inter
Between-trial variance of the interaction
effecta
0, 0.005, 0.05, 0.5 V2
Fixed-parameters
Number of patients included in each trial between 30 and 199 patients in small trials, and 200
and 400 patients in large trials
j
Ratio of small to large trials 1:1 –
Number of trial arms 2 treat
Ratio of randomization 1:1 –
Magnitude of the treatment effecta −1 beta.treat
Between-trial variance of the treatment
effecta
0.063 V1
Effect of age on the outcome 0.05 age
Random intercept variance 0.25 σ2
Random slope variance 0.04 τ2
Correlation between random intercept
and random slope variances
0.8 ρ
Age of individual patients N(mean. age, variance. age) age
Mean age of patients within trials N(67,20.25) mean. age
Variance of age within trials N(49, 1) variance. age
aOn a 0 to 10 visual analogue scale
bSee Eq. 4.1
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to 10 VAS1 at the end of treatment on the jth patient in
the ith trial, treatij and ageij are, respectively, the treat-
ment received (a binary indicator variable coded 0 for
the control group and 1 for the Naproxen group) and
age of the jth patient in the ith trial, beta.treati is the
between-group difference in mean VAS (i.e. treatment
effect) in trial i and comes from a normal distribution
with mean − 1 and variance V1, beta.interi is the inter-
action between the treatment effect and age in trial i, uij
and vij are, respectively, the random intercept and the
random slope of the treatment effect on the jth patient
in the ith trial, and res.var. is the residual variance of
knee OA pain in the ith trial. age is a continuous vari-
able, with a mean that was drawn from a normal distri-
bution with mean of 67 and variance of 20.25, and a
variance was drawn from a normal distribution with
mean 49 and variance of 1, which allowed the variation
of mean.age and variance.age across simulated trials.
beta.inter comes from a normal distribution with mean
δ and variance V2. δ was set as − 0.01 for the main ana-
lysis and as 0 for a sensitivity analysis to assess model
performance when there is actually no interaction effect.
The δ of − 0.01 assumes that the treatment effect im-
proves by − 0.01 (as a negative effect means a larger
treatment effect in this case) by every increase of 1 year
in age. V2 was set as 0.05 (high but plausible heterogen-
eity) for the main analysis and as 0.5 (implausible high
heterogeneity), 0.005 (low heterogeneity) or 0 (no het-
erogeneity) for sensitivity analyses. uij and vij are as-
sumed to follow a multivariate normal distribution with
mean 0, a variance–covariance matrix ∑, and correlation
ρ of 0.8. The variance of the random intercept repre-
sented by σ2 and the variance of the random slope of the
treatment effect by τ2 and they have a correlation ρ.
Thus, this model simulates heterogeneity both in treat-
ment effects and in interaction effects, but the latter is
usually not modelled in meta-analysis.
Varying parameters for data generation
It was of interest to assess the performance of the
models under different scenarios commonly relevant to
evidence synthesis. Of main interest was to see how
model performance was dependent on: the number of
trials included in the meta-analysis; the magnitude of
the interaction effect between treatment effect and age;
and the magnitude of the between-trial heterogeneity of
the interaction effect (Table 1). Our estimand θ, the
interaction effect, was assumed to be − 0.01 or 0 on a 0
to 10 VAS. An interaction effect of − 0.01 means that for
every 10 years increase in patients’ age, the treatment
effect comparing Naproxen and placebo will increase by
− 0.1, which means that Naproxen will have a linear in-
crease in its effect as compared to placebo as patients
get older. This is based on an assumption that older pa-
tients will have more pain at baseline, and that treatment
effects are directly proportional to pain at baseline. A
null interaction effect (i.e. 0) assumes that the treatment
effect does not vary according to patients’ age.
1The actual simulated VAS values were not restricted within 0 and 10
to maintain a near normal shape of yij to ensure our results were
generalizable to analyses assuming a Gaussian distribution.
Table 2 Simulated scenarios used to compare the performance
measures of different models.
Interaction effect
-0.01 0
Number
of trials
Between-trial variance in
the interaction effect
Number
of trials
Between-trial variance in
the interaction effect
6 0 6 0
10 0 10 0
16 0 16 0
20 0 20 0
26 0 26 0
30 0 30 0
40 0 40 0
50 0 50 0
6 0.005 6 0.005
10 0.005 10 0.005
16 0.005 16 0.005
20 0.005 20 0.005
26 0.005 26 0.005
30 0.005 30 0.005
40 0.005 40 0.005
50 0.005 50 0.005
6 0.05 6 0.05
10 0.05 10 0.05
16 0.05 16 0.05
20 0.05 20 0.05
26 0.05 26 0.05
30 0.05 30 0.05
40 0.05 40 0.05
50 0.05 50 0.05
6 0.5 6 0.5
10 0.5 10 0.5
16 0.5 16 0.5
20 0.5 20 0.5
26 0.5 26 0.5
30 0.5 30 0.5
40 0.5 40 0.5
50 0.5 50 0.5
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Thus, model performance was assessed in 64 different
simulated scenarios (Table 2). These datasets had 6, 10,
16, 20, 26, 30, 40, or 50 trials, an interaction effect be-
tween the treatment effect and age of − 0.01 or 0, and a
between-trial variance of the interaction effect of 0 (no
heterogeneity), 0.005 (low heterogeneity), 0.05 (high but
plausible heterogeneity), or 0.5 (implausible high hetero-
geneity). All simulated datasets had an even number of
trials, so that datasets could be equally divided into trials
with a low or large number of patients included, as ex-
plained below.
Fixed parameters for data generation
The simulation scenarios described above all shared the
same fixed parameters (Table 1) regarding: number of
patients included in each trial; number of trial arms; the
ratio of randomization; the magnitude of the treatment
effect; the between-trial variance of the treatment effect;
and the effect of age on knee OA pain. Each of these is
described in turn below.
Number of patients included in the trial: half of the trials
in the simulated dataset were small and half were large.
Trials were considered large if they had on average at least
100 patients in each arm [17]. The total number of pa-
tients included in each trial varied randomly between 30
and 199 patients in small trials, and 200 and 400 patients
in large trials.
Number of trial arms: all trials had two arms.
Ratio of randomization: all trials had a 1:1
randomization.
Magnitude of the treatment effect: the magnitude of the
treatment effect was an effect size of − 1 on a 0 to 10 VAS,
favoring patients that received high dose Naproxen as
compared to those who received placebo (i.e. lower pain
on average among patients that received Naproxen than
those that received placebo). Assuming a standard devi-
ation of 2.5, this corresponds to a small to moderate, and
minimally clinically relevant effect of − 0.4 standard devi-
ation units, which was the reported effect of high dose Na-
proxen as compared to placebo in a recently published
network meta-analysis of RCTs comparing different types
of non-steroidal anti-inflammatory drugs to placebo for
the treatment of patients with knee OA [16].
Between-trial variance of the treatment effect: we used
a moderate between-trial variance of 0.063. This as-
sumes that the treatment effect comes from a normal
distribution with approximately 95% of the trial effects
ranging between − 1.5, which is considered a moderate
to large treatment effect in knee OA in favour of Na-
proxen, to 0.5, indicating a small, clinically irrelevant
treatment effect in favour of placebo.
Effect of age on knee OA pain: it was assumed that the
slope of age in knee OA pain would correspond to a
yearly increase in pain of 0.05 on a 0 to 10 VAS.
Software used to generate simulated data
Data were simulated in Stata 14.2 using the 64-bit Mers-
enne twister for random number generation. The input
seed was ‘1234’.
Code for data generation
The code used for data generation is presented in Add-
itional file 1: Appendix A to facilitate reproducibility and
understanding of the methods used in this simulation
study.
Estimand
The estimand θ is the interaction effect between the
treatment effect and age, which is described in the
models below as beta.interC. That is, the magnitude by
which the treatment effect changes for every unit in-
crease in age.
Models assessed
The performance of seven different models were com-
pared. Models 1, 2, and 3 were based on the proposed
model by Riley et al. for IPD meta-analysis, which sepa-
rates within- from between-trial estimation of treatment
effects, as a way to minimize the risk of ecological fallacy
(Table 3) [18].
Model 1: Estimation of the between-trial variance of
the interaction between treatment effect and age, estima-
tion of the between-trial variance of the treatment effect,
and separation of within- from between-trial interaction
effects, using individual patient data. Separation of
within- from between-trial interaction effects was imple-
mented as previously suggested by Riley et al. [18]. Al-
though we are not aware it has ever been fitted in
practice, this model is considered the gold-standard in
this investigation because it estimates the random-
effects of both interaction effect and treatment effect
that exist in the simulated dataset, and also separates the
within and between-trial interaction effects.
In this model, ageCij is the covariate ageij centered by its
mean value mi, in each trial, and it includes an interaction
term between the treatment effect and ageCij, as well as
an interaction term between the treatment effect and mi,
to separate the within- from the between-trial effects:
yij ¼ αþ treatijbeta:treat
 
þ ageCijbeta:ageC
 
þ treatijageCijbeta:interC
 
þ ageMibeta:ageM
 
þ treatijageMibeta:interM
 þ ui
þ v1itreatijageCij þ v2itreatij ð4:2Þ
where yij is the predicted knee OA pain measured on a 0
to 10 VAS on the jth patient in the ith trial, α is the
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average knee OA pain in the placebo group for patients
that have an average age, treatij and ageCij are, respect-
ively, the treatment received and age centered around
the trial’s mean age of the jth patient in the ith trial,
ageMi is the mean age of patients in the i
th trial, beta.-
treat is the fixed between-group difference in knee OA
pain (i.e. treatment effect), beta.ageC is the fixed coeffi-
cient of the centered age covariate, beta.interCi is the
interaction between the treatment effect and centered
age in trial i, beta.ageM is the fixed coefficient of the
mean value of the age covariate, beta.interM is the fixed
interaction between the treatment effect and the mean
value of age, ui are the random trial effects of knee OA
pain in the placebo group for patients that have an aver-
age age, v1i are the random trial effects in the interaction
between the treatment effect and centered age, and v2i
are the random trial effects in the treatment effect. This
model assumes an exchangeable covariance structure be-
tween the random-effects of intercept and interaction.
As previously stated, this model allows the separation of
the pooled within-trial treatment-covariate interaction
beta.interC from the between-trials interaction beta.in-
terM [18]. This model has been shown to completely
separate within- and between-trial effects, thus resulting
in independent beta.interC and beta.interM, even when
the number of subjects per study is small [18, 19]. The
between-trials interaction beta.interM is actually the
same as the output of a meta-regression, which only uses
aggregate data to estimate associations between
individual-level characteristics and the treatment effect
(model 7 is a meta-regression) [20].
.Model 2: Estimation of the between-trial variance of
the interaction between treatment effect and age, and
separation of within- from between-trial interaction ef-
fects, using individual patient data.
yij ¼ αþ treatijbeta:treat
 
þ ageCijbeta:ageC
 
þ treatijageCijbeta:interC
 
þ ageMibeta:ageM
 
þ treatijageMibeta:interM
 þ ui
þ vitreatijageCij ð4:3Þ
The parameters in model 2 are as defined previously in
model 1, except that now the only random trial effects are
Table 3 Description of each of the models used in the analysis and their differences to the gold-standard model 1
Model Description Difference from model 1
1 − Model for analysis of individual patient data
− Estimation of the between-trial variance of the interaction between
treatment effect and age
− Estimation of the between-trial variance of the treatment effect
− Separation of within- from between-trial interaction effects
–
2 − Model for analysis of individual patient data
− Estimation of the between-trial variance of the interaction between
treatment effect and age
− Separation of within- from between-trial interaction effects
− No estimation of the between-trial
variance of the treatment effect
3 − Model for analysis of individual patient data
− Estimation of the between-trial variance of the treatment effect
− Separation of within- from between-trial interaction effects
− No estimation of the between-trial
variance of the interaction between
treatment effect and age
4 − Model for analysis of individual patient data
− Estimation of the between-trial variance of the interaction between
treatment effect and age
− Estimation of the between-trial variance of the treatment effect
− No separation of within- from between-trial interaction effects
− No separation of within- from
between-trial interaction effects
5 − Model for analysis of individual patient data
− Estimation of the between-trial variance of the interaction between
treatment effect and age
− No separation of within- from between-trial interaction effects
− No estimation of the between-trial
variance of the treatment effect
− No separation of within- from
between-trial interaction effects
6 − Model for analysis of individual patient data
− Estimation of the between-trial variance of the treatment effect
− No separation of within- from between-trial interaction effects
− No estimation of the between-trial
variance of the interaction between
treatment effect and age
− No separation of within- from
between-trial interaction effects
7 − Model for analysis of aggregate data
− Estimation of the between-trial variance of the treatment effect
− Model for analysis of aggregate data
− No estimation of the between-trial
variance of the interaction between
treatment effect and age
− No separation of within- from
between-trial interaction effects
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in the interaction between the treatment effect and cen-
tered age vi. Again, separation of within- from between-trial
interaction effects was implemented as previously suggested
by Riley et al. [18].
Model 3: Estimation of the between-trial variance of the
treatment effect, and separation of within- from between-
trial interaction effects, using individual patient data.
yij ¼ αþ treatijbeta:treat
 
þ ageCijbeta:ageC
 
þ treatijageCijbeta:interC
 
þ ageMibeta:ageM
 
þ treatijageMibeta:interM
 þ ui
þ vitreatij ð4:4Þ
The parameters in model 3 are as defined previously
in model 1, except that now the only random trial effects
are in the treatment effect vi. Again, separation of
within- from between-trial interaction effects was imple-
mented as previously suggested by Riley et al. [18].
Model 4: Estimation of the between-trial variance of
the interaction between treatment effect and age, estima-
tion of the between-trial variance of the treatment effect,
without separation of within- from between-trial inter-
action effects, using individual patient data
yij ¼ αþ treatijbeta:treat
 
þ ageCijbeta:ageC
 
þ treatijageCijbeta:interC
 
þ ui
þ v1itreatijageCij þ v2itreatij ð4:5Þ
The parameters in model 4 are as defined previously in
model 1, except that mean age is no longer part of the
model. This means that the association between mean age
and the outcome of knee pain, and the interaction effect
between mean age and treatment allocation on the out-
come of knee pain, are no longer estimated. Because mean
age is not included in model 4, it does not separate the
within- from between-trial interaction effects.
Model 5: Estimation of the between-trial variance of
the interaction between treatment effect and age, without
separation of within- from between-trial interaction ef-
fects, using individual patient data.
yij ¼ αþ treatijbeta:treat
 
þ ageCijbeta:ageC
 
þ treatijageCijbeta:interC
 
þ ui
þ vitreatijageCij ð4:6Þ
The parameters in model 5 are as defined previously
in model 2, except for the parameters related to the ef-
fect of mean age within trials. Because these parameters
were removed, model 5 does not separate the within-
from between-trial interaction effects.
Model 6: Estimation of the between-trial variance of
the treatment effect, without separation of within-
from between-trial interaction effects, using individual
patient data
yij ¼ αþ treatijbeta:treat
 
þ ageCijbeta:ageC
 
þ treatijageCijbeta:interC
 
þ ui
þ vitreatij ð4:7Þ
The parameters in model 6 are as defined previously
in model 2, except for the parameters related to the ef-
fect of mean age within trials. Because these parameters
were removed, model 6 does not separate the within-
from between-trial interaction effects.
Model 7: Estimation of the between-trial variance of
the treatment effect using aggregate data, which can only
estimate the between-trial interaction effects
yi ¼ αþ ageMibeta:age
 þ ui
ui  N 0; σ2
  ð4:8Þ
where yi is the predicted between-group difference in
knee OA in the ith trial, α is the fixed between-group dif-
ference in knee OA pain, ageMi is the mean age of pa-
tients in the ith trial, beta.age is the fixed interaction
effect between the treatment effect and the mean age of
patients in the ith trial, and ui is the random effect of the
between-group difference in knee OA pain.
Performance measures
Bias, coverage, empirical and model-based standard er-
rors, and the relative error in the model standard error
for the estimand θ were assessed. Estimation of perform-
ance measures and their Monte Carlo Standard Error
(MCSE) was conducted as described by Morris et al.
[15]. Bias was considered acceptable if it was ≤10 times
lower than the simulated interaction effect of − 0.01.
Coverage of the 95% confidence interval of the estimated
interaction effect was assessed. The explanation on how
each of the performance measures were calculated are
presented in Additional file 1: Appendix B.
Sample size calculation
The simulation was powered to have a precise esti-
mate of coverage. With an expected coverage of 95%,
and a desired MCSE of coverage of 0.5%, 1900 repeti-
tions would be needed [15]. It was then decided to use
2000 repetitions for each simulation, which results in
a small MCSE for the estimate of all performance
measures (Table 4).
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Software used to analyse the performance of the simulated
data
All analyses were conducted in Stata 14.2.
Results
In this section, we focus on results pertaining to the
large but plausible between-trial variation of 0.05 in the
interaction effect since our main purpose is to assess
model performance when this variation is taken into ac-
count. Results of other scenarios using a between trial
variation of different magnitude are presented in the
Additional file 1.
Results of simulations assuming a large between-trial
variation of 0.05 in the interaction effect
Figure 1 shows the interaction effects estimated in each
of the 2000 repetitions according to all models for ana-
lyses with 6, 20, and 50 trials and the large between-trial
variation of 0.05 in the interaction effect. It can be seen
from this graph that the interaction effects from models
that used IPD have a much narrower scatter than those
from model 7, the only model that used AD. Through
visual inspection, the mean value of the interaction ef-
fects appears similar across all models. Also, the scatter
of interaction effects decreases as the number of trial in-
creases, for all of the models.
Figure 2 shows scatter plots of interaction effects of all
models plotted against each other. It can be seen that
there is a considerable agreement between all models
Table 4 Largest Monte Carlo Standard Errors (MCSE) expected
with 2000 simulations for each of the performance measures of
interest
Estimate MCSE
Bias ≤0.03
Coverage ≤0.05
Empirical SE ≤0.0005
Model SE ≤0.0005
Relative error in the model SE ≤0.018
SE standard error
Fig. 1 Scatter of interaction effects from 2000 repetitions for each of the models for analyses with 6, 20, and 50 trials
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that used IPD, with higher agreement between models
that made the same assumptions regarding between-trial
variation of effects. It can also be seen that there is very
low correlation between results from models using IPD
and the model 7, which used AD. Although increasing
the number of trials decreased the variation of estimates
for all models, it did not have an important influence in
the correlation between the results of different models.
Figure 3 shows the standard error of the interaction ef-
fects according to all models for analyses with 6, 20, and
50 trials. As with the interaction effects, this graph
shows that the scatter of standard errors is narrower in
models that used IPD than model 7, which used AD.
Again, as with the interaction effect, the scatter of the
standard error decreases as the number of trials in-
creases. However, different than what was observed with
the interaction effects, the mean value of the standard
error in model 7 was systematically larger than those in
models that used IPD.
Figure 4 shows scatter plots of the standard error of
interaction effects of all models plotted against each
other. As previously observed for interaction effects,
there is a higher correlation in standard errors between
models that used the same assumptions regarding the
estimation of between-trial variance. Although there was
a clear correlation in standard errors between models
that used IPD, this correlation is lower than the one ob-
served for interaction effects. As with interaction effects,
an increase in the number of trials did not increase the
correlation of standard errors between models, and the
correlation between models using IPD and model 7 was
very low.
Table 5 shows the estimated bias in the interaction ef-
fect in each of the models for all investigated number of
trials. Bias was most influenced by whether the between-
trial variation was estimated for the interaction effect, the
treatment effect, or both. A separate estimation of within-
and between-trial effects did not play an important role. It
can be seen that bias tends to decrease as the number of
trials increases for all of the models, with a more extensive
difference in model 7, which used aggregate data. While
all other models had a satisfactory bias with a lower num-
ber of trials, model 7 had a bias effect of − 0.065, which is
6.5 times the simulated interaction effect of − 0.01. Model
7 only has an acceptable bias of 0.0007 when 50 trials are
included in the analysis. Among the models that used IPD
(i.e. models 1–6), only models that modelled exclusively
the between-trial variation of the interaction effect (i.e.
models 2 and 5) performed well when the number of trials
was only 6. Model 2, which modelled the between-trial
variation in the interaction effect and separated within-
and between-trial effects, had the lowest bias (− 0.00006).
Model 5, which modelled the between-trial variation in
interaction effects but did not separate within- from
Fig. 2 Comparison between models of estimates of interaction
effects across 2000 repetitions for 6, 20, and 50 trials
da Costa and Sutton BMC Medical Research Methodology          (2019) 19:198 Page 9 of 19
between-trial effects, had also an acceptable bias of
0.00038. With 10 trials included in the analysis, the mag-
nitude of bias becomes acceptable for models that exclu-
sively modelled the between-trial variation of the
treatment effect (i.e. models 3 and 6). Only when 16 trials
were included in the analysis that models 1 and 4, which
modelled between-trial variation for both treatment effects
and interaction effects, achieved acceptable levels of bias.
Finally, the MCSE was relatively large for all bias
estimates.
Table 6 shows the observed coverage of the interaction
effect between treatment effect and age in each of the
models. With only 6 trials, coverage was best with model
7, with an observed coverage of 94.4%, while all models
using IPD had an observed coverage below 90%. Cover-
age was worst with models that exclusively estimated the
between-trial variance in treatment effects, with ob-
served values around 83.4%. As the number of trials in-
creased, coverage also increased, but models using IPD
consistently overestimated coverage, with observed
coverage values always lower than the nominal value.
For models using IPD, those that estimated the
between-trial variation in the interaction effect had
acceptable coverage levels when at least 20 trials were
included in the analysis. Models 3 and 5 only had an ac-
ceptable coverage when 40 trials were included in the
analysis. Among models using IPD, those that estimated
the between-trial variation in the interaction effect had
consistently better coverage than models that did not.
Coverage was consistently accurate for model 7 across
all numbers of trials. Finally, all coverage estimates were
precise, with low MCSEs.
Figures 5, 6 and 7 display zip plots of the 2000 confi-
dence intervals for all IPD models for analyses with 6,
20, or 50 trials (see Additional file 1: Appendix B for an
explanation on how to interpret zip plots). We can read-
ily see that all models using IPD had insufficient cover-
age when only 6 trials were included in the analysis,
with models 3 and 6, which only addressed the between-
trial variance of the treatment effect, having the worst
coverage. With 20 trials included in the analysis, we can
see that coverage is appropriate for most models, but
that models 3 and 6 are still slightly overestimating the
nominal coverage. With 50 trials included in the analysis
it becomes clear that all models using IPD have an ap-
propriate coverage.
Fig. 3 Scatter of standard error of the interaction effects for each of the models for analyses with 6, 20, and 50 trials
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Table 7 shows how each model performed in the estima-
tion of standard errors, for different numbers of trials in-
cluded in the analysis. In general, both empirical and model
SEs were smaller in models 1 and 4, where the between-
trial variance of treatment effects and interaction effects are
estimated and allowed for. Models 2 and 5, which estimate
and allow for the between-trial variance in interaction ef-
fects only, had the second smallest empirical and model
SEs. Among models using IPD, models 3 and 6, which esti-
mated and allowed for the between-trial variance in treat-
ment effects, but ignored the between-trial variance in
interaction effects, yielded the largest SEs, and thus have
the lowest precision. Model 7, the only model that used
AD, yielded clearly higher SEs than the other models. The
difference in SEs between models using IPD were small.
These findings were not affected by the number of trials in-
cluded in the analysis, or whether within- and between-trial
effects were modelled separately or together. When asses-
sing the error in the model SE in relation to the empirical
SE, the model SE was most accurate if the model also esti-
mated and accounted for the between-trial variance in
interaction effects (models 1,2,4,5), while models that ig-
nored this had a consistently higher relative error in the
model SE (models 3,6,7). This pattern was consistent re-
gardless of the number of trials included in the analysis, or
if within- and between-trial effects were modelled separ-
ately or together.
Table 8 shows the mean squared error of each model
for different numbers of trials included in the analysis. It
can be seen that the mean squared error decreased as
the number of trials included in the analysis increased,
that models using IPD have lower mean squared errors
than the model that used AD, and that models that
accounted for the between-trial variance in the inter-
action effect had a lower mean squared error than those
that did not. The most important factor leading to
higher values of the mean squared error was the use of
AD for the analysis. The model that used AD had con-
siderably larger mean squared errors than models that
used IPD. Although the mean squared error decreased
as the as the number of trials included in the analysis
increased, it was still considerably higher for the model
using AD even when 50 trials were included in the analysis.
Among models that used IPD, differences in mean squared
error seem negligible, even though models that accounted
for the between-trial variance in the interaction effect had
lower mean squared errors than those that did not.
Results of simulations assuming a null, small, or
implausible large between-trial variation in the
interaction effect
Results of the simulation with a between-trial variance of
zero, 0.005, or 0.5 are shown in Additional file 1: Appendi-
ces C, D and E. Findings of our simulation with a null or
Fig. 4 Comparison between models of estimates of standard errors
of interaction effects across 2000 repetitions for 6, 20, and 50 trials
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small between-trial variance were similar to the simulations
with a large but plausible between-trial variance, but with
much smaller differences between models using IPD. Dif-
ferences in performance between models using IPD and
the model using AD decreased as the between-trial vari-
ation decreased. The difference in all performance mea-
sures between the models using IPD were consistently
small, with a pattern indicating that models that allowed
for the between-trial variance in the interaction effect had
lower bias, and better precision and coverage. Again, similar
to the simulations assuming a large but plausible between-
trial variance, the model using AD had a generally worse
performance than models using IPD. Although this differ-
ence in performance decreased as the number of trials in-
creased, the model using AD still had a worse performance
than models using IPD even when 50 trials were included
in the analysis, albeit unimportant differences. No relevant
difference was observed between models that separated
within- and between-trial associations and models that did
not separate them.
Findings of our simulation with an implausible large
between-trial variance were similar to those from the sim-
ulations with a large but plausible between-trial variance.
However, the difference in performance between models
was accentuated with the implausible large between-trial
variance, mainly when the number of trials included in
the analysis was low.
Results of simulations assuming a null interaction effect
Results from analyses assuming a null interaction ef-
fect were remarkably similar to those from analyses
assuming an interaction effect of − 0.01 (results avail-
able on request).
Discussion
Main findings
In this simulation study, the performance of seven differ-
ent meta-regression models for the pooling across trials of
interaction effects between a patient-level characteristic
and the treatment effect were compared and it was
Table 5 Bias in the interaction effect between treatment effect and covariate (age) in each of the models in the presence of high
but plausible heterogeneity in the interaction effect
No. of
trials
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
6 0.00179 (0.09149) −0.00006
(0.09595)
0.00323 (0.10316) 0.00179 (0.09149) 0.00038 (0.09622) 0.00323 (0.10316) −0.06454
(1.87747)
10 −0.00101
(0.07082)
−0.00079
(0.07411)
− 0.00070
(0.08183)
− 0.00101
(0.07082)
− 0.00072
(0.07410)
−0.00070
(0.08183)
0.01286 (1.22375)
16 −0.00013
(0.05543)
−0.00060
(0.05795)
− 0.00094
(0.06589)
−0.00014
(0.05543)
− 0.00050
(0.05800)
−0.00094
(0.06589)
0.01857 (0.93068)
20 −0.00049
(0.05012)
−0.00102
(0.05260)
− 0.00119
(0.05889)
−0.00049
(0.05012)
− 0.00097
(0.05254)
−0.00119
(0.05889)
− 0.02249
(0.81903)
26 −0.00051
(0.04289)
− 0.00079
(0.04524)
0.00012 (0.05107) − 0.00051
(0.04289)
−0.00076
(0.04517)
0.00012 (0.05107) −0.01126
(0.67902)
30 −0.00013
(0.04099)
0.00051 (0.04331) 0.00018 (0.04889) −0.00013
(0.04099)
0.00049 (0.04323) 0.00018 (0.04889) 0.00940 (0.62751)
40 0.00034 (0.03480) 0.00073 (0.03687) 0.00050 (0.04180) 0.00034 (0.03480) 0.00074 (0.03686) 0.00050 (0.04180) 0.01953 (0.55119)
50 −0.00010
(0.03198)
−0.00005
(0.03364)
− 0.00013
(0.03806)
−0.00010
(0.03198)
− 0.00004
(0.03368)
−0.00013
(0.03806)
0.00074 (0.48328)
Values in brackets are Monte Carlo standard errors
Table 6 Observed coverage of the interaction effect between treatment effect and covariate (age) in each of the models, with a
nominal coverage of 95% in the presence of high but plausible heterogeneity in the interaction effect
No. of trials Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
6 0.89400 (0.00688) 0.88500 (0.00713) 0.83850 (0.00823) 0.89450 (0.00687) 0.88550 (0.00712) 0.83850 (0.00823) 0.94350 (0.00516)
10 0.92250 (0.00598) 0.92100 (0.00603) 0.88950 (0.00701) 0.92250 (0.00598) 0.92150 (0.00601) 0.88950 (0.00701) 0.95250 (0.00476)
16 0.92850 (0.00576) 0.92600 (0.00585) 0.90800 (0.00646) 0.92900 (0.00574) 0.92700 (0.00582) 0.90800 (0.00646) 0.94900 (0.00492)
20 0.93350 (0.00557) 0.93900 (0.00535) 0.92350 (0.00594) 0.93400 (0.00555) 0.93450 (0.00553) 0.92350 (0.00594) 0.94050 (0.00529)
26 0.94150 (0.00525) 0.94300 (0.00518) 0.93250 (0.00561) 0.94150 (0.00525) 0.94250 (0.00521) 0.93250 (0.00561) 0.95300 (0.00473)
30 0.93150 (0.00565) 0.93300 (0.00559) 0.91750 (0.00615) 0.93150 (0.00565) 0.93400 (0.00555) 0.91750 (0.00615) 0.94900 (0.00492)
40 0.94650 (0.00503) 0.93800 (0.00539) 0.93250 (0.00561) 0.94650 (0.00503) 0.93700 (0.00543) 0.93250 (0.00561) 0.94450 (0.00512)
50 0.94700 (0.00501) 0.94950 (0.00490) 0.93400 (0.00555) 0.94700 (0.00501) 0.94900 (0.00492) 0.93400 (0.00555) 0.95400 (0.00468)
Values in brackets are Monte Carlo standard errors
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observed that a better performance was obtained in
models that used IPD and that allowed for between-trial
variation of the interaction effect. Although models that
allowed for between-trial variation of the interaction effect
had a better performance than models that did not allow
for this variation, other model or dataset characteristics
played a more important role in model performance. The
main factor influencing the performance of models was
whether they used IPD or AD. Models based on IPD gen-
erally had acceptable levels of bias that were ten times
smaller than the simulated interaction effect of − 0.01
when ten or more trials were included in the analysis.
Biases in the model using AD were approximately two to
six times larger than the simulated interaction effect, and
was only acceptable when 50 trials were included in the
analysis. The model that used AD also had a considerably
lower precision than all models that used IPD, especially
when a low number of trials was included in the analysis,
although coverage of AD models was generally appropri-
ate even with a low number of trials in the analysis. The
second most important factor influencing the perform-
ance of the models was the number of trials included in
the analysis. In general, as the number of trials included in
the analysis increased, the performance of all models im-
proved. Another important factor that influenced model
performance was the magnitude of heterogeneity. Differ-
ences in performance between models was more evident
in the presence of high heterogeneity (i.e. large between-
trial variation of the interaction effect), which is not sur-
prising given only certain models acknowledge the possi-
bility of heterogeneity in interaction effects. The
performance of models was also influenced, to a lesser de-
gree, by whether the model allowed for between-trial vari-
ation of the interaction effect. Models that used IPD and
allowed for between-trial variation of the interaction effect
had the best performance, generally with lower bias, better
coverage, and higher precision than all other models. The
model with the worst performance among IPD models
was the one that allowed for between-trial variation in
treatment effects but ignored the between-trial variation
in interaction effects, and it is likely the most commonly
used model in practice for IPD analyses. The gold-
standard model, which was a model that allowed for
between-trial variation in both treatment and interaction
effects and used IPD, did not perform well when only ten
trials were analysed. No relevant difference was observed
Fig. 5 Adapted zip plots of the 2000 confidence intervals for all IPD models for analyses with 6 trials
da Costa and Sutton BMC Medical Research Methodology          (2019) 19:198 Page 13 of 19
between models that separated within- and between-trial
associations and models that did not separate them, which
is unsurprising, as differences in within- and between-trial
associations was not simulated in the dataset (i.e. eco-
logical biases were not simulated). Likewise, the presence
of an interaction effect did not seem to influence results,
since results of analyses assuming a null interaction effect
or an interaction effect of − 0.01 were remarkably similar.
Practical implications
This study shows that when investigating interaction ef-
fects in meta-regressions, using IPD with a model that
accounts for the between-trial variation of interaction ef-
fects is likely to result in more accurate results, with less
bias, better coverage, and higher precision, especially in
the presence of high heterogeneity of interaction effects.
Not enough importance has been given to modelling the
between-trial variation of interaction effects when pool-
ing them across trials, with technical papers about re-
gression models mainly focusing on modelling the
between-trial variation of the treatment effect [18, 20,
21]. The reason for this, perhaps, is because although
modelling the between-trial variation in interaction
effect improves the accuracy of results, this improve-
ment seems rather irrelevant in the absence of high het-
erogeneity. Nevertheless, it is important that the
between-trial variation in interaction effects is reported,
perhaps together with prediction intervals around the
interaction effect, so that readers can better appreciate
how high or how low this variation is [13]. In practice,
modelling both between-trial variations, of the inter-
action effect and treatment effect, may lead to model
convergence problems, especially if a low number of tri-
als is included in the analysis. The lowest number of tri-
als used in the present simulation analysis was six, and
no convergence problems were observed. Whenever
convergence problems are observed, researchers may try
modelling only the between-trial variation of interaction
effects, and only if the problem persists, try to model
only the between-trial variation of treatment effects. Re-
searchers should also always give precedence to IPD
over AD when conducting regression analyses to pool
interaction effects across trials, especially if the number
of trials is below 50, which is often the case. Our simula-
tion analysis indicates that if 50 trials with AD are in-
cluded in a meta-regression, results may be comparable
Fig. 6 Adapted zip plots of the 2000 confidence intervals for all IPD models for analyses with 20 trials
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to regression analyses using IPD, in terms of bias and
coverage. However, even when 50 trials with AD were
included in the meta-regression, precision was still con-
siderably lower than a regression analysis with 50 trials
with IPD. Thus, since most meta-regression analyses in-
clude only a few trials, every effort should be made to
access IPD when the main goal is to pool subgroup ef-
fects across trials. Interestingly, the model using AD had
a better coverage than models using IPD when the num-
ber of trials analysed was low. This is likely due to the
use of a Knapp-Hartung approach for estimating the
variance of the mean interaction effect estimate in the
AD model, which corrects the between study variance to
account for its uncertainty [22]. This correction, devel-
oped for AD models, has been shown to have a better
coverage performance of the 95% confidence interval
than other approaches that assume that the between
study variance is known [23]. Moreover, using IPD
when investigating subgroup effects in a regression
analysis will not only lead to results with better statis-
tical properties, but is also necessary to avoid eco-
logical fallacy [3]. Finally, because IPD is often only
available for a small proportion of the trials included
in a meta-analysis, an alternative approach would be
to combine the evidence from IPD and AD when con-
ducting such regression analyses, which is beyond the
scope of the present simulation study [24].
Strengths and limitations
The main strength of this simulation analysis is that it
mimicked characteristics commonly found in meta-
analyses. This simulation analysis allowed for a wide range
of number of trials included in the analysis, for a varying
number of patients included across trials included in the
analysis with a balanced mix of small and large trials, and
for scenarios with small and large between-trial variation
in the interaction effect. Because the motivation to con-
duct this investigation is future research of osteoarthritis
treatments, the simulated dataset used representative
magnitude and within- and between-trial variations of
treatment effects and average patient age observed in
osteoarthritis trials [16]. Moreover, the use of simulated
datasets allowed us to observe the statistical properties of
different meta-regression models without the potential
confounding influence of factors such as biases due to low
Fig. 7 Adapted zip plots of the 2000 confidence intervals for all IPD models for analyses with 50 trials
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Table 7 Standard error of the interaction effect between treatment effect and covariate (age) in each of the models in the presence
of high but plausible heterogeneity in the interaction effect
No. of
trials
Performance
measure
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
6 Empirical SE 0.09147
(0.00145)
0.09595
(0.00152)
0.10311
(0.00163)
0.09148
(0.00145)
0.09621
(0.00152)
0.10311
(0.00163)
1.87636
(0.02968)
Model SE 0.09125
(0.01059)
0.09486
(0.01456)
0.09568
(0.01640)
0.09125
(0.01059)
0.09528
(0.01454)
0.09568
(0.01640)
1.81917
(177.01665)
Relative error in
model SE
−0.24168
(1.72411)
−1.13917
(1.77644)
−7.20306
(1.70537)
− 0.24417
(1.72406)
− 0.97397
(1.77358)
−7.20303
(1.70537)
−3.04755
(2.09350)
10 Empirical SE 0.07081
(0.00112)
0.07410
(0.00117)
0.08183
(0.00129)
0.07081
(0.00112)
0.07410
(0.00117)
0.08183
(0.00129)
1.22368
(0.01935)
Model SE 0.07072
(0.00378)
0.07411
(0.00540)
0.07776
(0.00676)
0.07072
(0.00378)
0.07412
(0.00534)
0.07776
(0.00676)
1.23611
(36.09575)
Relative error in
model SE
−0.13873
(1.66686)
0.00346
(1.71505)
−4.96244
(1.65106)
−0.13683
(1.66689)
0.03390
(1.71257)
−4.96244
(1.65106)
1.01558
(1.86656)
16 Empirical SE 0.05543
(0.00088)
0.05794
(0.00092)
0.06588
(0.00104)
0.05543
(0.00088)
0.05800
(0.00092)
0.06588
(0.00104)
0.93050
(0.01472)
Model SE 0.05606
(0.00144)
0.05883
(0.00200)
0.06377
(0.00321)
0.05606
(0.00144)
0.05867
(0.00196)
0.06377
(0.00321)
0.92118
(10.53523)
Relative error in
model SE
1.13187
(1.65210)
1.53029
(1.68156)
−3.21023
(1.64405)
1.13079
(1.65209)
1.15699
(1.67359)
−3.21024
(1.64405)
−1.00201
(1.70189)
20 Empirical SE 0.05012
(0.00079)
0.05259
(0.00083)
0.05887
(0.00093)
0.05012
(0.00079)
0.05253
(0.00083)
0.05887
(0.00093)
0.81872
(0.01295)
Model SE 0.05005
(0.00089)
0.05253
(0.00128)
0.05719
(0.00207)
0.05005
(0.00089)
0.05253
(0.00130)
0.05719
(0.00207)
0.80839
(6.13561)
Relative error in
model SE
−0.14153
(1.61861)
−0.10115
(1.64049)
−2.86836
(1.62743)
−0.14211
(1.61860)
0.00514
(1.64349)
−2.86838
(1.62743)
−1.26192
(1.66352)
26 Empirical SE 0.04289
(0.00068)
0.04523
(0.00072)
0.05107
(0.00081)
0.04289
(0.00068)
0.04517
(0.00071)
0.05107
(0.00081)
0.67892
(0.01074)
Model SE 0.04404
(0.00054)
0.04615
(0.00074)
0.05064
(0.00127)
0.04404
(0.00054)
0.04612
(0.00074)
0.05064
(0.00127)
0.69302
(3.18236)
Relative error in
model SE
2.69132
(1.65593)
2.02827
(1.65925)
−0.83126
(1.64152)
2.69167
(1.65594)
2.10172
(1.65950)
−0.83126
(1.64152)
2.07716
(1.68652)
30 Empirical SE 0.04099
(0.00065)
0.04331
(0.00068)
0.04889
(0.00077)
0.04099
(0.00065)
0.04323
(0.00068)
0.04889
(0.00077)
0.62743
(0.00992)
Model SE 0.04073
(0.00040)
0.04282
(0.00058)
0.04681
(0.00092)
0.04073
(0.00040)
0.04278
(0.00058)
0.04681
(0.00092)
0.63396
(2.30260)
Relative error in
model SE
−0.63932
(1.59872)
−1.13154
(1.60574)
−4.27073
(1.57354)
−0.64006
(1.59871)
−1.03999
(1.60736)
−4.27072
(1.57354)
1.03939
(1.66192)
40 Empirical SE 0.03480
(0.00055)
0.03687
(0.00058)
0.04180
(0.00066)
0.03480
(0.00055)
0.03685
(0.00058)
0.04180
(0.00066)
0.55085
(0.00871)
Model SE 0.03545
(0.00022)
0.03722
(0.00034)
0.04099
(0.00053)
0.03545
(0.00022)
0.03719
(0.00034)
0.04099
(0.00053)
0.54445
(1.23398)
Relative error in
model SE
1.87182
(1.63128)
0.94769
(1.63044)
−1.92503
(1.59642)
1.87298
(1.63130)
0.93484
(1.62997)
−1.92503
(1.59642)
−1.16099
(1.60819)
50 Empirical SE 0.03198
(0.00051)
0.03364
(0.00053)
0.03806
(0.00060)
0.03198
(0.00051)
0.03368
(0.00053)
0.03806
(0.00060)
0.48328
(0.00764)
Model SE 0.03165
(0.00014)
0.03338
(0.00021)
0.03673
(0.00034)
0.03165
(0.00014)
0.03337
(0.00021)
0.03673
(0.00034)
0.48219
(0.75386)
Relative error in
model SE
−1.03205
(1.58095)
−0.79436
(1.59442)
−3.48739
(1.56226)
−1.03213
(1.58094)
−0.91692
(1.59272)
−3.48739
(1.56226)
− 0.22640
(1.61322)
Values in brackets are Monte Carlo standard errors
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methodological quality, which could hinder the proper in-
terpretation of the results.
The main limitation of the present investigation is the
definition of small and large heterogeneity. Heterogen-
eity is of great relevance to this investigation, since its
main goal is to compare models that appropriately ad-
dress it or not. The cut-offs used to define small and
large but plausible heterogeneity were arbitrarily chosen
to represent real datasets of osteoarthritis treatments.
However, one may argue that even the definition of a
small heterogeneity may not be so small, and that the
large but plausible heterogeneity may be unusually large
for datasets of real osteoarthritis clinical trials. This is
done consciously to err on the safe side. That is, because
the performance of this models can only be different in
the presence of heterogeneity, cut-offs of small and large
heterogeneity were chosen so that at least some hetero-
geneity was always present. We also analysed a simu-
lated dataset with an implausible high heterogeneity for
a better understanding of how models perform across
different values of between-trial variance.
Another limitation is that results are only generalizable
to trials using continuous outcomes, and arguably, only
to osteoarthritis trials. However, it is expected that simi-
lar results are observed in trials with binary outcomes.
In addition, although the performance of models that
separate within- from between-trial associations was
compared to the performance of models that do not, the
dataset was not simulated to have different within- and
between-trial associations of age and treatment effect.
Thus, it is not surprising that there was no difference
between models that separated or not these two types of
associations. Likewise, although simulated datasets in-
cluded small and large trials, we did not simulate small-
study effects [17]. Discordant results between small and
large trials may play a major role in the results of a
random-effects meta-analysis [11, 25]. Finally, IPD meta-
analysis of continuous outcomes are less subject to overfit-
ting and may accommodate a larger number of covariates
to account for potential confounding than IPD meta-
analysis of binary outcomes or meta-regression in general
[26–28]. Since the main purpose was to investigate the
practical implications of adding random-effects to an inter-
action test in an IPD meta-analysis, we did not extended
our simulations to scenarios where multiple confounding
variables may be present.
Previous research
This is the first investigation in continuous outcomes to
compare the models that used IPD and AD while ac-
counting for between-trial variation in the interaction ef-
fect. Lambert et al. conducted a simulation study to
compare fixed-effect regression analyses using IPD or
AD to estimate the interaction between treatment effects
and patient-level characteristics [6]. They reported that
AD can be used in meta-regression if a large number of
large trials is available, and concluded that AD can be
used to adequately estimate an interaction between the
treatment effect and trial-level characteristics, but that
IPD would be needed to accurately estimate an inter-
action between treatment effects and patient-level char-
acteristics. Similarly to their study, the current
simulation study compared IPD and AD for the estima-
tion of an interaction between treatment effects and
patient-level characteristics, but extended the investiga-
tion of Lambert et al. by comparing random-effects
models. Similar to their findings based on fixed-effect
models, our investigation in random-effects models con-
cluded that AD can be used to estimate interaction ef-
fects if a large number of trials is available, but that IPD
is needed when estimating an interaction between treat-
ment effects and patient-level characteristics, mainly due
to problems with ecological fallacy.
Stewart et al. conducted a similar investigation to ours
using a real dataset of 24 RCTs evaluating antiplatelet
agents for the prevention of pre-eclampsia in pregnancy, a
binary outcome [21]. They compared three different
models that were similar to the ones used in the present in-
vestigation: one model that had random-effects for the
treatment effect but had a fixed-effect for the interaction
Table 8 Mean squared error of the interaction effect between treatment effect and covariate (age) in each of the models in the
presence of high but plausible heterogeneity in the interaction effect
No. of trials Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
6 0.00837 (0.00027) 0.00920 (0.00029) 0.01064 (0.00034) 0.00837 (0.00027) 0.00925 (0.00029) 0.01064 (0.00034) 3.52311 (0.18382)
10 0.00501 (0.00016) 0.00549 (0.00017) 0.00669 (0.00022) 0.00501 (0.00016) 0.00549 (0.00017) 0.00669 (0.00022) 1.49681 (0.05581)
16 0.00307 (0.00010) 0.00336 (0.00011) 0.00434 (0.00014) 0.00307 (0.00010) 0.00336 (0.00011) 0.00434 (0.00014) 0.86574 (0.03416)
20 0.00251 (0.00008) 0.00277 (0.00009) 0.00347 (0.00011) 0.00251 (0.00008) 0.00276 (0.00009) 0.00347 (0.00011) 0.67048 (0.02303)
26 0.00184 (0.00006) 0.00205 (0.00007) 0.00261 (0.00008) 0.00184 (0.00006) 0.00204 (0.00007) 0.00261 (0.00008) 0.46083 (0.01572)
30 0.00168 (0.00005) 0.00187 (0.00006) 0.00239 (0.00008) 0.00168 (0.00005) 0.00187 (0.00006) 0.00239 (0.00008) 0.39357 (0.01326)
40 0.00121 (0.00004) 0.00136 (0.00004) 0.00175 (0.00005) 0.00121 (0.00004) 0.00136 (0.00004) 0.00175 (0.00005) 0.30366 (0.00986)
50 0.00102 (0.00003) 0.00113 (0.00004) 0.00145 (0.00004) 0.00102 (0.00003) 0.00113 (0.00004) 0.00145 (0.00004) 0.23345 (0.00767)
Values in brackets are Monte Carlo standard errors
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effect (corresponding to model 6 in the present study), one
model with the same characteristics of the previous one but
that separated the within- and between-trials associations
(corresponding to model 3 in the present study), and one
model that had random-effects for both the treatment ef-
fect and interaction effect and did not separate within- and
between-trials associations (corresponding to model 4 in
the present study). The authors concluded that results
across these models were virtually the same and led to the
same conclusions. This is somewhat different from the con-
clusions of the present study, as it was noticed that albeit
small, there were improvements in the accuracy of results
when the model allowed for random-effects of the inter-
action between treatment effect and covariate. This differ-
ence in conclusions may have happened for different
reasons. The first reason is that they had a fixed number of
24 trials in their analysis, and as shown in our analysis, dif-
ferences in performance between models are most evident
with a lower number of trials. Another reason is that there
was perhaps a low between-trial variation in the interaction
effect in their dataset. It was shown in this simulation that
the lower the between-trial variance, the less evident is the
difference in performance between models. Because we
conducted a simulation study which allowed us to vary sev-
eral parameters that could potentially play a role in the re-
sults of meta-analyses, as opposed to the study of Stewart
et al. which had only fixed parameters, we could observe
and compare the performance of all seven models through-
out a wide range of values from these parameters. Finally,
this simulation analysis was based on continuous outcomes,
while the analysis of Stewart et al. was based on a binary
outcome. It is unlikely that the difference in results ob-
served between the studies can be explained by this,
however.
Future research
Several future research questions could develop from the
current investigation. For instance, future research could
be conducted to develop and investigate whether a
model based on AD and that allows for between-trial
variation in interaction effects has a better performance
than the model based on AD that only allows for the
between-trial variation in the treatment effect. Future re-
search could also explore whether having lower or
higher number of trials than what was investigated in
the present study could play a role in the performance
of these models. Future research could also investigate if
similar results are observed with binary outcomes and if
the performance of the models change in the presence
of ecological fallacy, small study effects, or confounding
from single or multiple other sources. Future research
should also investigate more thoroughly the perform-
ance of different models for the estimation of the be-
tween trial variation in the interaction effect, including
an assessment of how this estimation or lack thereof
may influence the estimation of other parameters in the
model (e.g. is the between-trial variation of the treat-
ment effect overestimated if the interaction term is not
included in the model?). Also, the current study only in-
vestigates a single two-way interaction, but future stud-
ies may investigate more complex interactions, such as a
three-way interaction. Finally, future research should
consider investigating the use of permutation tests to
control for false positive rates to compare results of dif-
ferent regression models using these tests [27].
Conclusions
The results of the present investigation indicate that IPD
models that allow for the between-trial variation in
interaction effects should be given preference over
models that only allow for between-trial variation in
treatment effects when investigating subgroup effects
within a meta-analysis. It was shown that, even in the
absence of ecological fallacy, there is significantly less
bias and more precision when IPD is used over AD.
Among models using IPD, there was less bias, better
coverage, and higher precision in those that modelled
the between-trial variation in interaction effects (when
one existed), especially when a small number of trials
was analysed, and thus should be given precedence
whenever possible.
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